Postherpetic Neuralgia - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 98
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P1839D52806EN
Leaflet:

Download PDF Leaflet

Postherpetic Neuralgia - Pipeline Review, H2 2016
Postherpetic Neuralgia - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Postherpetic Neuralgia - Pipeline Review, H2 2016’, provides an overview of the Postherpetic Neuralgia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Postherpetic Neuralgia
  • The report reviews pipeline therapeutics for Postherpetic Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Postherpetic Neuralgia therapeutics and enlists all their major and minor projects
  • The report assesses Postherpetic Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Postherpetic Neuralgia
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Postherpetic Neuralgia Overview
Therapeutics Development
Pipeline Products for Postherpetic Neuralgia - Overview
Postherpetic Neuralgia - Therapeutics under Development by Companies
Postherpetic Neuralgia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Postherpetic Neuralgia - Products under Development by Companies
Postherpetic Neuralgia - Companies Involved in Therapeutics Development
Aestus Therapeutics, Inc.
ContraVir Pharmaceuticals, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Immune Pharmaceuticals Inc.
Jiangsu Hengrui Medicine Co., Ltd.
KPI Therapeutics, Inc.
Lpath, Inc.
Merck & Co., Inc.
Patagonia Pharmaceuticals, LLC
Pfizer Inc.
Phosphagenics Limited
Relmada Therapeutics, Inc.
Scilex Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd.
Toray Industries, Inc.
Postherpetic Neuralgia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(amitriptyline + ketamine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATX-08001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bupivacaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-746 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-05195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
funapide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FV-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketoprofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride patch - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lpathomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mepivacaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirogabalin besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-8291 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PATN-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REL-1017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRK-700 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
U-2902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zucapsaicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Postherpetic Neuralgia - Dormant Projects
Postherpetic Neuralgia - Discontinued Products
Postherpetic Neuralgia - Product Development Milestones
Featured News & Press Releases
Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
May 12, 2016: SCILEX Pharmaceuticals Study Suggests Underutilization of Recommended First-Line Lidocaine Patches and Opioid Overuse for Treatment of Pain Associated with Post-Herpetic Neuralgias
Apr 22, 2016: SCILEX Pharmaceuticals Reports First-Line Treatments Including Lidocaine Patches for Post-Herpetic Neuralgia Are Significantly Underutilized
Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
Dec 10, 2015: SCILEX Pharmaceuticals Announces Executive Hires
Sep 16, 2015: FDA Accepts SCILEX Pharmaceuticals' NDA Filing for ZTlido
Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
Apr 02, 2015: Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia
Feb 20, 2015: ContraVir Pharmaceuticals Provides Clinical Update on FV-100
Feb 19, 2015: Xenon Pharmaceuticals Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
Jan 07, 2015: ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100
Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia
Aug 11, 2014: Scilex Pharmaceuticals Completes Trial Enrollment for Ztlido
Jul 14, 2014: SCILEX Pharmaceuticals Commences Dermal Safety Studies of Ztlido
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Postherpetic Neuralgia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Postherpetic Neuralgia - Pipeline by Aestus Therapeutics, Inc., H2 2016
Postherpetic Neuralgia - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
Postherpetic Neuralgia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Postherpetic Neuralgia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Postherpetic Neuralgia - Pipeline by Immune Pharmaceuticals Inc., H2 2016
Postherpetic Neuralgia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
Postherpetic Neuralgia - Pipeline by KPI Therapeutics, Inc., H2 2016
Postherpetic Neuralgia - Pipeline by Lpath, Inc., H2 2016
Postherpetic Neuralgia - Pipeline by Merck & Co., Inc., H2 2016
Postherpetic Neuralgia - Pipeline by Patagonia Pharmaceuticals, LLC, H2 2016
Postherpetic Neuralgia - Pipeline by Pfizer Inc., H2 2016
Postherpetic Neuralgia - Pipeline by Phosphagenics Limited, H2 2016
Postherpetic Neuralgia - Pipeline by Relmada Therapeutics, Inc., H2 2016
Postherpetic Neuralgia - Pipeline by Scilex Pharmaceuticals, Inc., H2 2016
Postherpetic Neuralgia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
Postherpetic Neuralgia - Pipeline by Toray Industries, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Postherpetic Neuralgia - Dormant Projects, H2 2016
Postherpetic Neuralgia - Dormant Projects (Contd.1), H2 2016
Postherpetic Neuralgia - Dormant Projects (Contd.2), H2 2016
Postherpetic Neuralgia - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Postherpetic Neuralgia, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Aestus Therapeutics, Inc.
ContraVir Pharmaceuticals, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Immune Pharmaceuticals Inc.
Jiangsu Hengrui Medicine Co., Ltd.
KPI Therapeutics, Inc.
Lpath, Inc.
Merck & Co., Inc.
Patagonia Pharmaceuticals, LLC
Pfizer Inc.
Phosphagenics Limited
Relmada Therapeutics, Inc.
Scilex Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd.
Toray Industries, Inc.
Skip to top


Ask Your Question

Postherpetic Neuralgia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: